No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ADCT ADC Therapeutics
- 4.710
- +0.300+6.80%
Close May 1 16:00 ET
- 4.620
- -0.090-1.91%
Post 16:08 ET
390.05MMarket Cap-1602P/E (TTM)
4.850High4.350Low398.74KVolume4.440Open4.410Pre Close1.82MTurnover0.63%Turnover RatioLossP/E (Static)82.81MShares6.04052wk High-2.63P/B297.81MFloat Cap0.36052wk Low--Dividend TTM63.23MShs Float56.590Historical High--Div YieldTTM11.34%Amplitude0.360Historical Low4.568Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
Medifast Reports Mixed Results, Joins Coursera, Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Tuesday.Shares of Medifast, Inc. (NYSE:MED) fell sharply in today's pre-market trading after the com
Express News | HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $9 Price Target
Buy Rating Affirmed for ADC Therapeutics on Strong Preclinical Data and Promising Trial Progress
Analysts Conflicted on These Healthcare Names: ADC Therapeutics (ADCT), Adial Pharmaceuticals (ADIL) and Steris (STE)
ADC Therapeutics Showcases Cancer Treatment Innovations
Comments
Update
$ADC Therapeutics(ADCT.US$ ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination With Glofitamab or Mosunetuzumab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Moomoo 24/7· 5 mins ago
ADC Therapeutics SA (NYSE:ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with bispecific antibodies glofitamab or mosunetuzum...
Moomoo 24/7· 5 mins ago
ADC Therapeutics SA (NYSE:ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with bispecific antibodies glofitamab or mosunetuzum...
ADC Therapeutics' low P/S ratio may be due to poor growth and declining revenue. The company's underwhelming revenue outlook and shareholders' pessimism on revenue prospects contribute to the low P/S. The share price is unlikely to rise strongly soon.
ColumnsADC Therapeutics | LOTIS-9 Combo Study Takes a Breather on Enrollment
ADCT before market open today announced its voluntary pause in the enrollment of the LOTIS-9 combo trial of Zynlonta and Rituxan (Lonca-R) in front-line unfit/frail DLBCL. We also caught up with the mgmt team this morning for more insights. Briefly, the pause was driven by higher-than-expected respiratory-related TEAEs (incl. 7 Gr 5, 5 Gr 3/4) after a recent data review of 40 pts. Of the 12 TEAEs, 1 Gr 5 case was deemed to be r...
$ADC Therapeutics(ADCT.US$ big space to rebound.
$ADC Therapeutics(ADCT.US$ good news🔥
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg